| Nom du produit | Sémaglutide |
|---|---|
| Numéro CAS | 910463-68-2 |
| Formule moléculaire | C187H291N45O59 |
| Poids moléculaire | 4113.58 |
| Apparence | Poudre blanche à blanc cassé |
| Pureté (HPLC) | ≥98% |
| Colis | 5g, 10g, 50g per container |
Besoin d'aide ? Contacter notre équipe

Synonyms: Semaglutide, 910463-68-2, GLP-1 receptor agonist, GLP-1 analog, Semaglutide (USAN), Ozempic, Wegovy
Semaglutide is a synthetic analog of the human glucagon-like peptide-1 (GLP-1), a key incretin hormone that regulates glucose metabolism and appetite. It is a 31-amino acid peptide with a fatty acid side chain that enables extended half-life and once-weekly dosing. Developed for the treatment of type 2 diabetes and obesity, semaglutide has become a benchmark in the growing class of GLP-1 receptor agonists.
The molecule was engineered by substituting specific amino acids and attaching a C18 fatty diacid via a hydrophilic spacer, which promotes strong binding to albumin and slows renal clearance. This structural design allows for maintaining therapeutic concentrations over a week, a significant improvement over earlier GLP-1 analogs that required daily injections. Semaglutide is also being investigated for cardiovascular benefits and non-alcoholic steatohepatitis (NASH), reflecting its expanding clinical relevance.
As a research-grade peptide, semaglutide is supplied for laboratory use, including preclinical studies, analytical method development, and formulation research. It is typically offered as a lyophilized powder with a purity of at least 98% by HPLC, ensuring reliable performance in a range of experimental settings.
| Paramètre | Spécifications |
|---|---|
| Essai (HPLC) | ≥98,01 TP3T |
| Apparence | Poudre blanche à blanc cassé |
| Teneur en eau (KF) | ≤8.0% |
| Acetate Content (if applicable) | 5.0–12.0% |
| Endotoxin Level | ≤5 EU/mg |
Room,5-0203, Courtyard 205, Lianhu District,Xi'an,Shaanxi,China